Multiple Dose Safety Study of PF-04802540 in Subjects With Schizophrenia

• Status: Completed
• Trial end date: 2009-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of multiple ascending doses of PF-04802540 administered orally to subjects with schizophrenia.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Taisho Pharmaceutical Co., Ltd.

Criteria

Inclusion Criteria:

• Males or females of non-childbearing capacity aged 18 to 55 years inclusive

• DSM-IV diagnosis of schizophrenia, stable symptoms for at least 3 months

• Body mass index in the range of 18 to 40 kg/m2 and body weight>45 kg.

Exclusion Criteria:

• Evidence or history of a primary DSM IV axis I diagnosis other than schizophrenia.

• Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease

• Any condition possibly affecting drug absorption (eg, gastrectomy).